Being wrong should cost a second, not a decade.
Elyris Labs is building the computational layer for oncology drug discovery. We think the way a drug is chosen is about to change, and that the change is computational, not biological.
The waste
Around nine in ten candidates that enter clinical development never reach approval. Bringing one drug to market costs billions of dollars and well over a decade, carrying every one of those failures. Almost none of that is the price of discovering something works. It is the price of discovering that something does not, years after the decision to pursue it and long after the evidence that would have said so existed.
The mission
Today a candidate is picked on a plate, defended in an animal and tested in a person. Each step is slower and more expensive than the last. The information that would have stopped a bad program almost always existed earlier than the step that finally revealed it. It was never computed because, until recently, it could not be.
We compute it: one place where a compound, a genotype and a tissue are put together and questioned before a program commits to any of them. Where the answer that comes back is one a scientist can argue with.
The standard
In December 2022 the FDA Modernization Act 2.0 removed the statutory requirement that a drug be tested in animals before it can enter human trials, and named computational modeling among the alternatives. That changed what is allowed to count as evidence. It did not produce any.
A computational result earns its place when a reviewer can audit it: a stated method, a stated uncertainty, a provenance chain, a clean line between what was measured and what was inferred. We build to that bar, not to the opening.
What you get
You bring your compounds. You get back which are selective in which tumor genotypes, whether they reach the cells that matter, how new chemistry with no data reads, and for conjugates whether the payload reaches cells the antibody never touched. Every call is a receipt.
Why it compounds
A program that dies early returns its budget, bench time and people to the pipeline while all three are still worth something. Do it across every program, every quarter, and capital efficiency stops being a line item and starts to compound, the way interest does. Being wrong quickly and cheaply, over and over, is worth more than being right slowly.
The team
A specialized group of computational, biological and complex-systems engineers. We do not write software about biology. We build digital twins, work out how drugs move through tissue, and run the infrastructure a pharmaceutical company will put its chemistry on.
Architect of LURA end to end. A systems engineer who builds digital twins from scratch.
Former Global Health Fellow at Rice360. Microphysiological systems and transport modeling. The scientific anchor between what the software claims and what a wet lab can show.
Complex technical project management and industrial operations, previously at American Electric Power. Turns modeling into enterprise pipelines that hold under load.
Cloud architecture and distributed control systems. Builds the multi-tenant deployment layer that keeps each customer's data isolated.
Twenty years of clinical engineering and global regulatory practice, holding LURA to the international validation standards it will eventually be read against.
The company
- Legal entity
- Elyris Labs Inc.
- Headquarters
- Fort Worth, Texas, United States
- Programs
- Member, NVIDIA Inception
- Enquiries
- info@elyrislab.com
- Confidentiality
- How we handle your data